PTO/SB/08a (08-03)
Approved for use through 97/31/2006, OMS 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

		Application Number			
	DMATION DIGGI COURT	Filing Date		2006-06-08	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Noirot et al.		First Named Inventor	Noirot et al.		
(Not for submission under 37 CFR 1.99)		Art Unit			
Examiner Name	of Submission under or or it is any	Examiner Name			
Attorney Docket Number 5850		Attorney Docket Number	r	5850	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	of sited Document		Relev	Pages,Columns,Lines where Relevant Passages or Releval Figures Appear		
	1	4857624		1989-08-15	DeBlasi et al.					
	2	4784163		1988-11-15	Adams et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear			
	1									
If you wish	h to a	dd additional U.S. Publ	shed Ap	plication citatio	n information	please click the Ad	d butto	n. Add		
				FOREIGN PA	TENT DOCUM	MENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Publication Date	Name of Patentee or Applicant of cited Document Pages, Columns, where Relevant Passages or Rel Figures Appear		evant or Relevant	T6	
	1	0548506	EP		1993-06-30	93-06-30 Hoechst AG				
	2	1031587	EP		2000-08-30	Vianova Resins Gr Co KG	mbH &			

	Application Number		
	Filing Date		2006-06-08
INFORMATION DISCLOSURE	First Named Inventor Noirot		t et al.
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		
(NOTION SUBMISSION UNIQUE ST OFR 1.33)	Examiner Name		
	Attorney Docket Number	er	5850

	3	19947	939	DE		2001-04-19	Bender		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner Cite Inducte name of the author (in CARITAL LETTERS), title of the article (when appropriate), title of the item (hote), magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T6		
1									
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Examiner Signature Date Considered								

See Knd Code of USPTO Patent Documents at insex_ISETO_GOL/ or MPEP 901.04. 2 finite of this that issued the document, by the love-left code (WIPO Standard 513.). For Laplanese patent counters, the ancidated on the spent of the Emptor runny precess the sent number the patent document. If Ancidated 513.0 finite process the sent number to patent document. If Ancidated 511.0 finite passable, Spanish spent of the Emptor runny precess the sent number to patent document. If Ancidated 511.0 finite passable, Spanish spent of the Spanish springer sent resistance is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Application Number | Fing Date | 2006.06.08 | Find Number | Fing Date | 2006.06.08 | First Number | Noird et al. | Art Unit | Carminer Name | Attorney Docket Number | 5850 | Application Number | 5

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication of forms a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c) in the control of the control

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Charles Fallow/	Date (YYYY-MM-DD)	2006-06-08
Name/Print	Charles W. Fallow	Registration Number	28946

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3231-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.